惠泰医疗
(688617)
| 流通市值：415.12亿 | | | 总市值：415.12亿 |
| 流通股本：1.41亿 | | | 总股本：1.41亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 564,276,710.67 | 2,065,801,597.74 | 1,524,828,925.89 | 1,000,959,631.54 |
| 营业收入 | 564,276,710.67 | 2,065,801,597.74 | 1,524,828,925.89 | 1,000,959,631.54 |
| 二、营业总成本 | 357,739,406.5 | 1,339,013,056.93 | 970,562,004.58 | 636,098,674.02 |
| 营业成本 | 151,862,192.91 | 571,958,608.18 | 416,428,949.37 | 272,793,146.59 |
| 税金及附加 | 6,982,321.54 | 24,712,011.56 | 18,406,178.09 | 12,296,432.74 |
| 销售费用 | 98,074,722.76 | 372,819,791.52 | 270,401,595.52 | 177,190,097.33 |
| 管理费用 | 30,390,749.64 | 91,518,138.58 | 67,592,585.98 | 46,293,844.04 |
| 研发费用 | 73,969,533.27 | 290,539,080.33 | 202,856,157.35 | 133,893,513.26 |
| 财务费用 | -3,540,113.62 | -12,534,573.24 | -5,123,461.73 | -6,368,359.94 |
| 其中:利息费用 | 1,165,671.63 | 2,005,246.3 | 1,573,495.68 | 1,083,633.83 |
| 其中:利息收入 | 3,929,076.97 | 12,062,256.7 | 9,411,332.22 | 6,585,343.35 |
| 加:公允价值变动收益 | - | - | 1,466,434.16 | 867,793.72 |
| 加:投资收益 | 4,494,466.92 | 13,170,904.11 | 11,484,718.93 | 7,271,182.22 |
| 资产处置收益 | -350.61 | 253,318.97 | 43,588.26 | 22,819.68 |
| 资产减值损失(新) | -99,291.93 | -24,627,584.36 | -1,947,032.87 | -1,911,269 |
| 信用减值损失(新) | -846,911.09 | -2,691,471.27 | -1,182,653.42 | -870,244.31 |
| 其他收益 | 5,583,694.34 | 40,797,719.15 | 25,177,876.3 | 19,539,399.96 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 215,668,911.8 | 753,691,427.41 | 589,309,852.67 | 389,780,639.79 |
| 加:营业外收入 | 3,975.26 | 281,885.74 | 106,424.95 | 119,830.92 |
| 减:营业外支出 | 1,853,371.2 | 8,006,034.62 | 2,649,827.26 | 1,629,996.4 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 213,819,515.86 | 745,967,278.53 | 586,766,450.36 | 388,270,474.31 |
| 减:所得税费用 | 33,684,373.99 | 87,799,537.81 | 64,715,837.72 | 50,214,273.67 |
| 六、净利润 | 180,135,141.87 | 658,167,740.72 | 522,050,612.64 | 338,056,200.64 |
| 持续经营净利润 | 180,135,141.87 | 658,167,740.72 | 522,050,612.64 | 338,056,200.64 |
| 归属于母公司股东的净利润 | 183,151,687.9 | 673,151,713.17 | 528,146,736.78 | 342,560,640.88 |
| 少数股东损益 | -3,016,546.03 | -14,983,972.45 | -6,096,124.14 | -4,504,440.24 |
| (一)基本每股收益 | 1.89 | 6.96 | 5.44 | 5.12 |
| (二)稀释每股收益 | 1.88 | 6.92 | 5.42 | 5.1 |
| 八、其他综合收益 | -138,078.4 | -22,575,353.34 | 10,593,158.2 | 10,584,528.89 |
| 归属于母公司股东的其他综合收益 | -138,078.4 | -21,132,118.23 | 11,434,330.27 | 11,425,700.96 |
| 九、综合收益总额 | 179,997,063.47 | 635,592,387.38 | 532,643,770.84 | 348,640,729.53 |
| 归属于母公司股东的综合收益总额 | 183,013,609.5 | 652,019,594.94 | 539,581,067.05 | 353,986,341.84 |
| 归属于少数股东的综合收益总额 | -3,016,546.03 | -16,427,207.56 | -6,937,296.21 | -5,345,612.31 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-26 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |